Advanced Bladder Cancer VL

Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo

Details
The anti-PD-L1 avelumab in urothelial carcinoma—A discussion with investigator Dr Andrea Apolo. The JAVELIN Solid Tumor phase 1, open-label, dose-escalation trial investigated avelumab, a human monoclonal anti-PD-L1 antibody (anti-PD-L1), in patients with selected tumor indications (eg, NSCLC, breast cancer, colorectal cancer). Pooled analysis of two JAVELIN cohorts that included patients with adv...

Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar

Details
Beyond Endpoints: An interview with Dr. Srikala Sridhar, study chair of the BL.12 trial Investigator-initiated trials (IITs) often tackle important questions that are not addressed elsewhere. [transcript] Compared with a pharmaceutical company–managed trials, benefits of IITs include generating data in a real-world setting and resolving issues that confound physicians in daily practice. A recent o...

Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III

Details
Black individuals with muscle-invasive bladder cancer (MIBC) experience 21% lower odds of guideline-based treatment (GBT). Differences in treatment account for 35% of observed Black-White differences in survival. Samuel Washington III, MD, MAS joins Ashish Kamat, MD, MBBS, to highlight this data published in Cancer Medicine. Low GBT levels demonstrated an "under-allocation" of GBT to those who nee...

Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden

Details
Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...

First-Line Maintenance Avelumab in Patients with advanced Urothelial Carcinoma, A New Standard of Care - JAVELIN Bladder 100 Journal Club - Christopher Wallis & Zachary Klaassen

Details
A new first-line standard of care -- JAVELIN Bladder 100 Platinum-based chemotherapy is currently the standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. In this Journal Club, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc review the JAVELIN Bladder 100 randomized, phase...

Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde

Details
Guru Sonpavde joins Alicia Morgans, MD, MPH in a discussion on the treatment landscape of muscle-invasive bladder cancer and several trials that could lead to changes in treatment patterns across the bladder cancer disease spectrum. They review data recently presented at the 2020 European Society for Medical Oncology Virtual Congress, (ESMO) including sacituzumab govitecan in Cohort 3 of the TROPH...

Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta

Details
Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...

The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo

Details
Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...

Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...

Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar

Details
Makarand Khochikar, President of the Urological society of India –West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj, joins Ashish Kamat, MD to discuss the case of a 70-year-old patient who presented with left-side loin pain and intermittent hematuria. An ultrasound and CT scan revealed a solid-lesion in the left kidney, lesions in the left...